Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition comprising rebamipide as active ingredient for preventing or treating hyperlipemia and diseases associated therewith

A technology for hyperlipidemia and rebamipide, applied in the field of rebamipide, can solve problems such as side effects, and achieve the effects of improving fatty liver, increasing expression, and improving blood lipids

Active Publication Date: 2015-07-08
THE CATHOLIC UNIV OF KOREA IND ACADEMIC COOPERATION FOUND
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Among these, lovastatin, simvastatin, pravastatin, etc. are the most well-known cholesterol-lowering agents that inhibit HMG-CoA reductase in the early stage of cholesterol biosynthesis, but also inhibit the synthesis of steroid hormones and dolichols , thus causing severe side effects (Havel, R.L. et al., Ann. Internal Med., 107:609-615, 1987; Illingworth, D.R. and Bacon, S. Am. J. Cardiolopy 60: 33-42, 1987)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition comprising rebamipide as active ingredient for preventing or treating hyperlipemia and diseases associated therewith
  • Composition comprising rebamipide as active ingredient for preventing or treating hyperlipemia and diseases associated therewith
  • Composition comprising rebamipide as active ingredient for preventing or treating hyperlipemia and diseases associated therewith

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0096] Inflammatory cytokines based on rebamipide treatment of macrophages (inflammatory cytokines) generation inhibitory effect

[0097] In order to ascertain the effect of rebamipide on macrophages, the inventors of the present application pre-treated mouse (Mouse) macrophages with rebamipide, and utilized LPS (lipopolysaccharide; lipopolysaccharide) to stimulate, Thus, the inflammatory cytokines TNF-a (tumor necrosis factor-α; tumor necrosis factor-alpha), IL-6 (interleukin-6; interleukin-6) and IL-1β (interleukin-1β; The degree of production of interleukin-1β) was assessed by ELISA (enzyme linked immunosorbent assay) analysis.

[0098] Cell culture

[0099] RAW 264.7 cells, which are mouse macrophage cell lines, were distributed from the Korean Cell Line Bank (KCLB), and for cell culture, a culture medium containing 10% FBS and 1% penicillin-streptomycin (penicillin-streptomycin) was used. DMEM (Dulbeccos Modified Eagle Medium) medium. At 37°C, 5% CO 2 cells were...

Embodiment 2

[0106] Toxicity determination of rebamipide to cells

[0107] In order to examine the cytotoxicity of rebamipide against RAW 264.7, which is a mouse macrophage, an MTT assay (MTT assay) was performed.

[0108] This method measures the conversion of MTT (3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide; thiazolium blue) to formazan (Formazan) in a 96-well Packed in the plate 1×10 4 The cells / well (cells / well) of RAW 264.7 cells were treated with rebamipide according to the concentration (20, 100, 500, 1000, 5000 μM) for 18 hours. Add 100 μl of MTT solution to each well (well), so that at 37 ° C, 5% CO 2 The reaction was carried out in an incubator for 4 hours, and then the change in absorbance was measured at 570 nm using a microplate reader (VERSAmax, Molecular Devices, USA).

[0109] As a result, such as figure 2 As shown, the cytotoxicity is weak at concentrations of 20 μM, 100 μM and above, which are effective concentrations, and thus it can be seen that th...

Embodiment 3

[0111] Inhibitory effect of rebamipide-based treatment on vascular etiological cells

[0112] In this experiment, it was examined whether the generation of vascular etiogenic cells could be really inhibited when rebamipide treatment was performed in the vascular etiogenic cells. The "vascular etiological cell" refers to a foam cell (Foam cell) that forms a precursor cell of an arteriosclerotic plaque that causes arteriosclerosis, and is considered to be a cell that causes arteriosclerosis. In the invention, it is arbitrarily named as vascular etiological cell.

[0113] Inhibitory effect of rebamipide-based treatment on vascular etiological cells

[0114] In order to carry out this experiment, THP1 cells, a human macrophage cell line, were treated with PMA (phorbol 12'-myristate 13'-acetate; 12'-myristate-13'-acetate phorbol) at a concentration of 160nM to activate the cells , and then PAF (platelet-activating factor; platelet-activating factor) was treated with 10ug / ml,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical use of rebamipide to be used in preventing or treating hyperlipemia and diseases associated therewith, and more particularly, to a composition comprising rebamipide as an active ingredient for preventing or treating hyperlipemia and diseases associated therewith. The rebamipide compound according to the present invention may: inhibit the generation of TNF-a, IL-6 and IL-1b which are hyperlipemia-inducing inflammatory cytokines secreted by macrophage; inhibit the generation of foam cells which form artherosclerotic plaque precursor cells; lower the levels of total cholesterol, LDL-cholesterol and neutral fat to improve blood lipid; improve fatty liver; inhibit an activity of B cells; and decrease the expression of Th17 for accelerating the generation of artherosclerotic plaque and increase the expression of Treg cells for controlling an inflammatory reaction. Accordingly, the rebamipide compound can be valuably used as a pharmaceutical composition for preventing or treating hyperlipemia and diseases associated therewith such as arteriosclerosis, heart failure and hypertensive heart disease through the above-described various mechanisms. Furthermore, the rebamipide compound is free from toxicity or side effects for a drug, and can therefore be used with an easy mind even over a long period of time, and has an effect of in-vivo stability.

Description

technical field [0001] The present invention relates to the pharmaceutical use of Rebamipide used in the prevention or treatment of hyperlipidemia and diseases related thereto, and in particular to the high content of Rebamipide contained as an active ingredient. Composition for prevention or treatment of lipemia and related diseases. Background technique [0002] Modern people's excessive intake of saturated fat and cholesterol due to the pursuit of Western European diet and lifestyle changes and the requirements of the era of convenience is considered to cause cardiovascular diseases such as obesity, hyperlipidemia, arteriosclerosis, and myocardial infarction. Systemic diseases, and lipid peroxides cause degenerative processes in organisms and promote cancer and aging, and change or destroy biofilms. Cholesterol in the blood has been proven to be a risk factor for ischemic cerebrovascular disease and coronary artery disease, and has been proven to be the cause of aging su...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4704A61P3/06A61P3/00
CPCA61K31/4704A61P3/00A61P3/06A61P9/00A61P9/04A61P9/06A61P9/10A61P9/12A61P43/00
Inventor 曹美罗闵俊基田周燕边财耿任艺彬金恩敬杨恩智郑静禧
Owner THE CATHOLIC UNIV OF KOREA IND ACADEMIC COOPERATION FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com